Stock Price Quote

ADVANCED ENZYME TECHNOLOGIES LTD.

NSE : ADVENZYMESBSE : 540025ISIN CODE : INE837H01020Industry : Pharmaceuticals & DrugsHouse : Private
BSE363.501.95 (+0.54 %)
PREV CLOSE ( ) 361.55
OPEN PRICE ( ) 362.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 17678
TODAY'S LOW / HIGH ( )354.10 368.25
52 WK LOW / HIGH ( )249.05 425.1
NSE363.101.95 (+0.54 %)
PREV CLOSE( ) 361.15
OPEN PRICE ( ) 361.25
BID PRICE (QTY) 363.10 (80)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 231764
TODAY'S LOW / HIGH( ) 354.00 368.80
52 WK LOW / HIGH ( )249.25 425.15
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 15-03 1989
Management Info
Vasant Rathi - Chairman - Managing Director
Registered Office

Address Sun- Magnetica, A Wing,5th Floor, Near L I C Service Road,Louiswadi,
Thane,
Maharashtra-400604

Phone 022 41703200

Email info@advancedenzymes.com

Website www.advancedenzymes.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE

NEWS

06Mar Indian Hotels, Sonata Software and BHE
Indian Hotels Company has invested Rs 35 crore in the equity shares of Z..
05Mar Advanced Enzyme Technologies acquires
Advanced Enzyme Technologies has completed the acquisition of additional..
05Mar Update On Acquisition Of Additional S
Further to our letter dated February 10, 2024, we would like to inform t..
21Feb Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that it enclosed the Transcrip..
20Feb Advanced Enzyme Technologies informs a
Advanced Enzyme Technologies has informed that it enclosed the disclosur..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit191.2555.27
Gross Profit 253.56 742.78
Operating Profit 281.12846.96
Net Sales 911.413115.29

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE)
peergroup  6660.85 (7.79%)
M.Cap ( in Cr)8545.80
Concord Biotech (BSE)
peergroup  1561.65 (3.68%)
M.Cap ( in Cr)16337.39
Sanofi India (BSE)
peergroup  8490.90 (0.51%)
M.Cap ( in Cr)19555.07
JB Chem & Pharma (BSE)
peergroup  1800.50 (2.37%)
M.Cap ( in Cr)27942.82
Divi's Lab (BSE)
peergroup  3779.20 (1.08%)
M.Cap ( in Cr)100325.89

Shareholding Pattern

MUTUAL FUNDS/UTI 5.42%
PROMOTERS 43.62%
NON-INSTITUTION 26.87%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Advanced Enzyme Technologies Ltd.

Advanced Enzyme Technologies Ltd. was incorporated in the year 1989. Its today's share price is 363.5. Its current market capitalisation stands at Rs 4064.81 Cr. In the latest quarter, company has reported Gross Sales of Rs. 3123.46 Cr and Total Income of Rs.3213.37 Cr. The company's management includes Vandana Tilak, Sanjay Basantani, Nitin Jagannath Deshmukh, Rajshree Patel, Sunny Sharma, Vinodkumar Hiralal Jajoo, Pramod Kasat, Rasika Rathi, Mukund M Kabra, Vasant Rathi.

It is listed on the BSE with a BSE Code of 540025 , NSE with an NSE Symbol of ADVENZYMES and ISIN of INE837H01020. It's Registered office is at Sun- Magnetica, A Wing,5th Floor, Near L I C Service Road,LouiswadiThane-400604, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, MM Nissim & Co, MSKA & Associates, Walker Chandiok & Co LLP, Walker, Chandiok & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.